The efficacy of oxaliplatin combination adjuvant chemotherapy for elderly patients with stage III colorectal cancer.
Aged
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Chemotherapy, Adjuvant
/ adverse effects
Colorectal Neoplasms
/ drug therapy
Drug Monitoring
/ methods
Female
Geriatric Assessment
/ methods
Humans
Japan
/ epidemiology
Male
Medication Therapy Management
Neoplasm Staging
Oxaliplatin
/ administration & dosage
Survival Analysis
Time
adjuvant chemotherapy
adverse events
colorectal cancer
elderly
prognosis
Journal
Nagoya journal of medical science
ISSN: 2186-3326
Titre abrégé: Nagoya J Med Sci
Pays: Japan
ID NLM: 0412011
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
entrez:
14
12
2020
pubmed:
15
12
2020
medline:
25
9
2021
Statut:
ppublish
Résumé
Now we are facing to aging society. We aimed to determine the long-term outcomes receiving adjuvant chemotherapy among elderly patients with stage III colorectal cancer. Elderly patients (≧65 years, n=91) diagnosed as stage III colorectal cancer and received adjuvant chemotherapy were retrieved from the database and classified into two groups according to whether the patient received monotherapy (n=65) or doublet therapy(n=26). Recurrence-free survival and overall survival were compared between the groups. To balance the essential variables, we conducted propensity score matching. After one-to-one propensity score matching, each group consisted of 22 patients. No significant difference was detected by comprehensive geriatric assessment 7. Overall survival was significantly longer in the monotherapy group. Adverse events occurred more frequently in the doublet therapy group. Monotherapy may improve the long-term outcome of elderly patients while the adverse events were less frequent.
Identifiants
pubmed: 33311791
doi: 10.18999/nagjms.82.4.603
pmc: PMC7719450
doi:
Substances chimiques
Antineoplastic Agents
0
Oxaliplatin
04ZR38536J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-611Déclaration de conflit d'intérêts
The authors declare no conflict of interest for the present study.
Références
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369
pubmed: 29632055
Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52
pubmed: 16084735
J Clin Oncol. 2012 Jul 20;30(21):2624-34
pubmed: 22665536
N Engl J Med. 2018 Mar 29;378(13):1177-1188
pubmed: 29590544
J Clin Oncol. 2007 Jun 1;25(16):2198-204
pubmed: 17470851
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Cancer. 2012 Jul 1;118(13):3377-86
pubmed: 22072065
J Natl Compr Canc Netw. 2016 Nov;14(11):1357-1370
pubmed: 27799507
J Clin Oncol. 2016 Jul 10;34(20):2366-71
pubmed: 27185838
J Clin Oncol. 2011 Apr 10;29(11):1465-71
pubmed: 21383294
Ann Oncol. 2015 Apr;26(4):715-724
pubmed: 25595934
J Geriatr Oncol. 2018 Jan;9(1):84-86
pubmed: 28802840
Eur J Cancer. 2014 Sep;50(13):2231-40
pubmed: 24958736
JAMA. 1990 Sep 19;264(11):1444-50
pubmed: 2202842
J Clin Oncol. 2014 Aug 20;32(24):2570-80
pubmed: 25071118
J Clin Oncol. 2012 Jul 20;30(21):2576-8
pubmed: 22665545
J Clin Oncol. 2009 Jul 1;27(19):3109-16
pubmed: 19451431
Colorectal Dis. 2012 Jan;14(1):48-55
pubmed: 21689262
J Natl Compr Canc Netw. 2012 Feb;10(2):213-24; quiz 225
pubmed: 22308516
J Clin Oncol. 2011 Oct 1;29(28):3768-74
pubmed: 21859995
J Clin Oncol. 2013 Jul 10;31(20):2600-6
pubmed: 23733765
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2011 Sep 1;29(25):3457-65
pubmed: 21810685